US FDA Unveils AI Tool to Expedite Scientific Reviews, Reports Reuters – Investing.com

The U.S. Food and Drug Administration (FDA) has introduced a new artificial intelligence (AI) tool designed to streamline the scientific review process for medical products. This innovative technology aims to significantly shorten the time required for regulatory assessments, which can traditionally be lengthy and complex. By automating certain aspects of the review, the AI tool helps to enhance efficiency, allowing FDA officials to focus on more critical evaluations and decision-making. The move comes amidst growing pressure to expedite the approval of drugs and medical devices, especially in light of recent health crises. The FDA sees this initiative as part of a broader effort to modernize its operations and leverage advanced technology in the regulatory landscape. Overall, the AI tool represents a significant step forward in improving the FDA’s capabilities to ensure safety and efficacy while responding promptly to public health needs.

Source link